Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted...
Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1...
Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China
France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...
Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands
Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...
Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...
Eli Lilly Partners with Creyon Bio to Develop RNA-Targeted Therapies
Eli Lilly and Company (NYSE: LLY) announced a strategic collaboration with Creyon Bio, Inc., a...
AbbVie’s Rinvoq Gains FDA Approval for Giant Cell Arteritis
US-based pharma giant AbbVie (NYSE: ABBV) announced regulatory approval from the US Food and Drug...
Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma
German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...
Itcure and OBiO Technology Partner to Advance Gene Editing and VLP Delivery Systems
Itcure, a gene editing specialist based in Suzhou, has entered into a partnership with compatriot...
Fosun Pharma Partners with Fakeeh Care Group to Advance Biopharmaceuticals in Saudi Arabia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced a strategic partnership...
Fosun Pharma Reports Q1 2025 Revenues of RMB 9.42 Billion, Net Profits of RMB 765 Million
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) released its Q1 2025...
Roche’s VENTANA TROP2 Device Receives FDA Breakthrough Designation
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that its VENTANA TROP2 (EPR20043) RxDx...
Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-5635 in Chronic HBV
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...
BeiGene Wins USPTO Ruling Invalidating Pharmacyclics’ Patent Claims
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...
Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...
United Imaging Healthcare Reports 9.73% Revenue Decline in 2024 Financials
China-based device giant United Imaging Healthcare (UIH, SHA: 688271) released its 2024 financial report, recording...
Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma
China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...